Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics
VKTX Price/Volume Stats
| Current price | $27.40 | 52-week high | $81.73 |
| Prev. close | $26.57 | 52-week low | $18.92 |
| Day low | $26.19 | Volume | 2,316,500 |
| Day high | $27.44 | Avg. volume | 4,396,162 |
| 50-day MA | $26.48 | Dividend yield | N/A |
| 200-day MA | $45.08 | Market Cap | 3.08B |
VKTX Stock Price Chart Interactive Chart >
Viking Therapeutics, Inc. (VKTX) Company Bio
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
VKTX Price Returns
| 1-mo | 16.10% |
| 3-mo | -10.10% |
| 6-mo | -44.74% |
| 1-year | -60.32% |
| 3-year | 1,041.67% |
| 5-year | 285.92% |
| YTD | -31.91% |
| 2024 | 116.23% |
| 2023 | 97.98% |
| 2022 | 104.35% |
| 2021 | -18.29% |
| 2020 | -29.80% |
Loading social stream, please wait...